EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
Relevance. From 600 thousand to 1.2 million cases of ARVI and influenza are registered annually in Kazakhstan. On the average for the epidemiological season hospitalised with severe and medium - severe course of ARVI - up to 70-80 thousand people, 70% of whom are children under 14 years, including children under 1 year - up to 30-35%, pregnant women -53-55% of the number of pregnant women who fall ill with ARVI, respectively. Treatment of acute respiratory viral infectious disease (ARVI) includes a number of measures and approaches aimed at alleviating symptoms, reducing the duration of the disease and preventing complications. One such drug is enisamia iodide, produced by Pharmak (Ukraine) under the trade name Amizon, registered in the Republic of Kazakhstan as an antiviral agent.
Materials and methods. The study is a cohort, clinical, non-interventional, prospective. In the city infectious diseases hospital of Shymkent, clinical trials were conducted on the effectiveness of the antiviral drug enisamia iodide in severe forms of ARVI in adults, in comparison with a group of patients who did not receive etiotropic treatment from December 2022 to January 2023.
Results and conclusions. As a result of the treatment, progression of normalization of body temperature was observed by the 4th and 5th days (96% and 98%, respectively). In the comparison group, an improvement in the normalization of body temperature by the 3rd day was registered in 60% of patients.
When comparing the main and control groups by bed days, statistically significant differences were established (p=0.049*). Patients with standard therapy stayed in the hospital longer than those who received Amizon additionally. During treatment with Amizon, only 1 case out of 50 developed an adverse event in the form of a minor headache coinciding with the drug intake, which did not require discontinuation of the drug. On the 3rd and 4th days of therapy, statistically significant differences were revealed. Regression of intoxication symptoms (fever, chills, headache, body aches) and catarrhal manifestations occurred much earlier than in the control group. The need to prescribe antibacterial drugs during the use of Amizon was 10%, which indicates its antiviral and antibacterial effect.
Gulzhan N. Abuova1, https://orcid.org/0000-0002-1210-2018
Kazybek Zh. Khangeldy1, https://orcid.org/0000-0002-5656-0918
Gulbanu G. Shaimerdenova1, https://orcid.org/0009-0000-6455-2769
Bagila A. Zhorakhanova1, https://orcid.org/0009-0000-9374-1681
Dana K. Sadykhova1,
1 South Kazakhstan Medical Academy, Department of Infectious Diseases and Dermatovenerology, Shymkent, Republic of Kazakhstan.
1. Баранов А.М., Шкрабов А.В., Шустер А.М., Галкина И.В. Клинико-экономическая эффективность применения Амизона при лечении гриппа и ОРВИ у детей // Российский вестник перинатологии и педиатрии. 2013. 58(3):82-86.
2. Данные комитета по санитарно-эпидемиологическому контролю Республики Казахстан, 2024 https://rk-ncph.kz/ru/sanepidem/ezhemesyachnaya-situatsiya (Дата обращения: 15.01.2024)
3. Кулжанова Ш.А., Нурахметова Г.А., Конкаева М.Е., Смагулова З.К. Клиническая эффективность препарата энисамия йодид в комплексном лечении ОРВИ // Медицина (Алматы). 2020. №5-6 (215-216). С. 32-37. DOI: 10.31082/1728-452X-2020-211-215-216-5-6-32-37
4. Медведева И.В., Калинина Л.А., Сухомлинов А.В., и др. Применение Амизона у детей с хроническими респираторными заболеваниями // Педиатрия. Журнал им. Г.Н. Сперанского. 2014. 93(1):34-39.
5. Петров В.А., Злотникова Е.И. Эксперименталь-ное исследование антивирусной активности Тилорона (Амизона) в отношении гриппа А/H5N1 и других возбудителей ОРВИ // Вопросы вирусологии. 2008. 53(6):38-42.
6. Сазонова М.А., Дудкин В.А., Старостина Е.Г., и др. Иммуномодулирующий препарат Амизон у детей с рецидивирующими респираторными вирусными инфекциями // Клиническая педиатрия. 2012. 2:31-35.
7. Boltz D., Peng X., Muzzio M. et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells // Antivir Chem Chemother. 2018. No 26. 2040206618811416. DOI: 10.1177/2040206618811416.
8. Casanova J.L., Abel L. The human model: a genetic dissection of immunity to infection in natural conditions // Nat. Rev. Immunol. 2004. Vol. 4 (1). P. 55–66. DOI: 10.1038/nri1264
9. Cocking D., Cinatl J., Boltz D.A. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus // Acta Virol. 2018. 62(2):191-195. doi: 10.4149/av_2018_211
10. Frolov A.F., Frolov V.M., Bukhtiarova T.A., Danilenko V.F. Clinical aspects of the use of Amizon // Ukrainian Medical Journal. 2004. 1(39):69–74.
11. Shaimerdenova G., Abuova G.N., Serikbayeva S. Antiviral Therapy in Pregnant Women with COVID-19 Archives of Clinical Infectious Diseases. 2023. 18 (1)e132803 https://doi.org/10.5812/archcid-132803 (Дата обращения: 12.01.2024)
12. Guo M., Ni J., Yu J. Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition // Int J Mol Sci. 2019 Dec 12;20(24):6261. doi: 10.3390/ijms20246261
13. Jones J.C., Marathe B.M., Lerner C. Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro // Antimicrob Agents Chemother. 2016 Aug 22. 60(9):5504-14. doi: 10.1128/AAC.00888-16
14. Governments continue discussions on pandemic agreement negotiating text. World Health Organization (WHO) https://www.who.int/com (Дата обращения: 12.01.2024)
15. Klinicheskie protokoly Ministerstva zdravookhraneniya Respubliki Kazakhstan – 2019: Gripp i ORVI (Kazakhstan). [Clinical protocols of the Ministry of Health of the Republic of Kazakhstan - 2019: Influenza and ARVI]. [Kazakhstan] https://diseases.medelement.com/disease/16085 (Дата обращения: 12.01.2024).
16. Kruker A.T., Krause M. Oseltamivir-induced delirium // Ther Umsch. 2010 Dec. Vol. 67 (12). P. 613-5. DOI: 10.1024/0040- 5930/a000106
17. Moscona A. Global transmission of oseltamivir-resistant influenza // N Engl J Med. 2009 Mar 5;360(10):953-6. doi: 10.1056/NEJMp0900648
18. Ramos I., Fernandez-Sesma A. Modulating the innate immune response to influenza A virus: potential therapeutic use of antiinflammatory drugs // Frontiers in immunology. 2015. No 6. P. 361. DOI: 10.3389/fimmu.2015.00361
19. Shaimerdenova G., Abuova G., Yelshibek G., Zhuparbek A., Bakytzhan G., Ashtayeva S. et al. The use of Remdesivir in pregnant women with COVID-19 // J Clin med kaz. 2023. 20(1):31-4. https://doi.org/10.23950/jcmk/12911 (Дата обращения: 13.08.2023)
20. Spencer S., Nguyen H., Elal A.A. et al. Surveillance for Oseltamivir Resistant Influenza A (H1N1) pdm09 Virus Infections During 2016–2017 and 2017–2018, United States // Open Forum Infectious Diseases. 2018. Vol. 5 (Suppl. 1). P. S267-S268. DOI: 10.1093/ofid/ofy210.752
References:
1. Baranov A.M., Shkrabov A.V., Shuster A.M., Galkina I.V. Kliniko-ekonomicheskaya effektivnost' primeneniya Amizona pri lechenii grippa i ORVI u detei [Clinical and economic effectiveness of Amizon in the treatment of influenza and ARVI in children]. Rossiiskii vestnik perinatologii i pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2013. 58(3):82-86 [in Russian]
2. Dannye komiteta po sanitarno-epidemiologicheskomu kontrolyu Respubliki Kazakhstan, 2024 [Data from the Committee for Sanitary and Epidemiological Control of the Republic of Kazakhstan] https://rk-ncph.kz/ru/sanepidem/ezhemesyachnaya-situatsiya [in Russian]
3. Kulzhanova Sh.A., Nurakhmetova G.A., Konkaeva M.E., Smagulova Z.K. Klinicheskaya effektivnost' preparata enisamiya iodid v kompleksnom lechenii ORVI [Clinical effectiveness of the drug enisamium iodide in the complex treatment of ARVI]. Meditsina (Almaty) Medicine]. 2020. №5-6 (215-216). pp. 32-37. DOI: 10.31082/1728-452X-2020-211-215-216-5-6-32-37 [in Russian]
4. Medvedeva I.V., Kalinina L.A., Sukhomlinov A.V., i dr. Primenenie Amizona u detei s khronicheskimi respiratornymi zabolevaniyami. Pediatriya [Application of Amizon in children with chronic respiratory diseases]. Zhurnal im. G.N. Speranskogo [Pediatrics. Journal named after G.N. Speransky]. 2014. 93(1):34-39. [in Russian]
5. Petrov V.A., Zlotnikova E.I. Eksperimental'noe issledovanie antivirusnoi aktivnosti Tilorona (Amizona) v otnoshenii grippa A/H5N1 i drugikh vozbuditelei ORVI [Experimental study of the antiviral activity of Tiloron (Amizon) against influenza A/H5N1 and other pathogens of ARVI]. Voprosy virusologii [Questions of Virology]. 2008. 53(6):38-42. [in Russian]
6. Sazonova M.A., Dudkin V.A., Starostina E.G., i dr. Immunomoduliruyushchii preparat Amizon u detei s retsidiviruyushchimi respiratornymi virusnymi infektsiyami [Immunomodulatory drug Amizon in children with recurrent respiratory viral infections]. Klinicheskaya pediatriya [Clinical Pediatrics]. 2012. 2:31-35. [in Russian]
Количество просмотров: 1252
Категория статей:
Актуальная тема COVID-19
Библиографическая ссылка
Abuova G.N., Khangeldy K.Zh., Shaimerdenova G.G., Zhorakhanova B.A., Sadykhova D.K. Efficacy of the antiviral drug enisamy iodide in severe adult acute respiratory infections in the COVID-19 era // Nauka i Zdravookhranenie [Science & Healthcare]. 2024, (Vol.26) 1, pp. 125-131. doi 10.34689/SH.2024.26.1.016Похожие публикации:
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
КЛИНИЧЕСКИЕ И СОЦИАЛЬНО-ДЕМОГРАФИЧЕСКИЕ ХАРАКТЕРИСТИКИ ПАЦИЕНТОВ С ПСИХИЧЕСКИМИ И ПОВЕДЕНЧЕСКИМИ РАССТРОЙСТВАМИ В ПОСТКОВИДНОМ ПЕРИОДЕ
ИММУНОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ У ДЕТЕЙ С МУЛЬТИСИСТЕМНЫМ ВОСПАЛИТЕЛЬНЫМ СИНДРОМОМ, АССОЦИИРОВАННЫМ С SARS-COV-2
КЛИНИЧЕСКАЯ КАРТИНА COVID-19 У ВЗРОСЛЫХ ПАЦИЕНТОВ ТУРКЕСТАНСКОЙ ОБЛАСТИ В ЗАВИСИМОСТИ ОТ СОПУТСТВУЮЩИХ ЗАБОЛЕВАНИЙ